Gradishar et al JCO 2009 / CBC2012
TOXICITY:
•
Most common AEs: alopecia, sensory
neuropathy, neutropenia, fatigue and arthralgia
•
G3/4 fatigue, neutropenia & febrile
neutropenia less frequent in all
nab
-paclitaxel
arms
•
Peripheral neuropathy similar in all arms
•
In 1L MBC there is superior efficacy and safety of weekly
nab
-paclitaxel vs docetaxel, with a
statistically & clinically significant prolongation of PFS (>5 mo) in pts receiving
nab
-paclitaxel
150 weekly vs docetaxel 100
Arm
PFS*
OS*
DoT*
Cycles
(nº)*
NabP300 11 mo
27.7 mo 22 mo 8
NabP150 12.9 mo 33.8 mo 38 mo 10
NabP 100 12.8 mo 22.2 mo 30 mo 8
Doce100
7.5 mo
26.6 mo 21 mo 8
•
NabP100 dose reductions occurred by cycle5 vs
Doce cycle3
•
Sensorial neuropathy was relevant (G3):
NabP300 21%
vs NabP100 9% vs
NabP 150 22%
vs Doce 12% but faster resolution in Nab P (22,
22 and 19d) vs 37d with Doce
Nab-paclitaxel: 1L trials
